Contemporary incidence and mortality rates of neuroendocrine prostate cancer

Anticancer Research

Volumn 35, Issue 7, 2015, Pages 4145-4150

  Alanee, Shaheen ^a   Moore, Aaron ^a   Nutt, Max ^a   Holland, Bradley ^a   Dynda, Danuta ^a   El Zawahry, Ahmed ^a   McVary, Kevin T ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 year survival; Androgen deprivation therapy; Incidence; Mortality; Neuroendocrine prostate cancer; Prostate; Prostate cancer

Indexed keywords

ADULT; AGE ADJUSTED INCIDENCE; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CARCINOID; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROECTODERM TUMOR; NEUROENDOCRINE PROSTATE CANCER; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SMALL CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA; UNITED STATES; ADOLESCENT; CANCER REGISTRY; CARCINOMA, NEUROENDOCRINE; INCIDENCE; MORTALITY; PROSTATIC NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARCINOMA, NEUROENDOCRINE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 84937157760     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA and Nanus DM: Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 30: e386-389, 2012.
2. Terry S and Beltran H: The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 4: 60, 2014.
3. Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA and Buttyan R: Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol 3: 67-75, 1997.
4. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Program (http://seer.cancer.gov/).
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS and Investigators A: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187-1197, 2012.
6. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS and Investigators C-A-: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13: 983-992, 2012.
7. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI and Investigators C-A-: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005, 2011.
8. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B and Investigators P: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371: 424-433, 2014.
9. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P and Rubin MA: Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38: 756-767, 2014.
10. Elliott SP, Jarosek SL, Wilt TJ and Virnig BA: Reduction in physician reimbursement and use of hormone therapy in prostate cancer. J Natl Cancer Inst 102: 1826-1834, 2010.
11. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B and Edwards BK: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100: 1672-1694, 2008.
12. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D and Edwards BK: Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105: 175-201, 2013.
13. Wang HT, Yao YH, Li BG, Tang Y, Chang JW and Zhang J: Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis - a systematic review and pooled analysis. J Clin Oncol 32: 3383-3390, 2014.
14. Galanis E, Frytak S and Lloyd RV: Extrapulmonary small cell carcinoma. Cancer 79: 1729-1736, 1997.
15. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P and Logothetis CJ: Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20: 3072-3080, 2002.
16. Cooperberg MR, Grossfeld GD, Lubeck DP and Carroll PR: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95: 981-989, 2003.
17. Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR and Van Den Eeden SK: Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol 32: 1324-1330, 2014.
18. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR and Investigators C: Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 106: 1708-1714, 2006.
19. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK and Smith MR: Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int 101: 1077-1083, 2008.
20. Bono A and Zurlo A: The EORTC Genito-Urinary Tract Cancer Group: 25 years of achievements and future strategies. Eur J Cancer 38(Suppl 4): S71-74, 2002.